Program
PORT-77
A development code.
Its studies are mostly in Protoporphyria, Erythropoietic, led by Portal Therapeutics.
Furthest: phase 3, since Aug 25, 20263 company-led studies, 1 open or runningNext primary completion: Mar 2029 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Portal Therapeutics | 31 open or running | phase 3since Aug 25, 2026 | Mar 21, 2024 | Mar 2029phase 3 · NCT07820085 |
Also a collaborator on its studies: celerion.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 21, 2024First study: phase 1 study in Healthy Adult ParticipantsFirst studyNCT06346509 · 156 enrolled · United States
- Apr 3, 2025Phase 2 study in Protoporphyria, ErythropoieticNCT06971900 · 28 enrolled · United States
- Aug 25, 2026Phase 3 study in Protoporphyria, ErythropoieticPhase 3 reachedNCT07820085 · 225 planned · United States
Ahead
- Mar 2029Primary completion: phase 3 study in Protoporphyria, ErythropoieticNCT07820085
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07820085Protoporphyria, Erythropoietic · United States | 3 | Recruiting | Mar 2029 | 225 |
| NCT06971900Protoporphyria, Erythropoietic · United States | 2 | Completed | Nov 22, 2025 | 28 |
| NCT06346509Healthy Adult Participants · United States | 1 | Completed | Dec 27, 2025 | 156 |
How it is read
Names in the registry
- “PORT-77”, 3 entries
Codes read as this program: PORT77.
Conditions, from the studies’ own filings
- Protoporphyria, Erythropoietic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.